What do we do with our under-enrolled single-center COVID-19 clinical trials?

Abstract

Get full access to this article

View all access options for this article.

References

Dean

Gsell

Brookmeyer

, et al. Creating a framework for conducting randomized clinical trials during disease outbreaks. N Engl J Med 2020; 382: 1366–1369.

Woodcock

LaVange

. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 2017; 377: 62–70.

Collins

Stoffels

. Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): an unprecedented partnership for unprecedented times. JAMA 2020; 323(24): 2455–2457.

Ellenberg

. Clinical trials in the time of a pandemic. Clin Trials 2020; 17(5): 467–471.

The RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med 2020; 383: 2030–2040.

World Health Organization. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19, 2020, https://www.who.int/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19 (2020, accessed 15 April 2021).

Eckhardt

Cummings

Rajagopalan

, et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials 2020; 21(1): 499.

Halpern

Karlawish

JHT

Berlin

. The continuing unethical conduct of underpowered clinical trials. JAMA 2002; 288(3): 358–362.

Petkova

Antman

Troxel

. Pooling data from individual clinical trials in the COVID-19 era. JAMA 2020; 324(6): 543–545.